Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21706030
Johnson N, et al. (2011) Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 17, 875-82 21706030
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S1189-p - BRCA1 (human)
Modsite: QKGELsRsPsPFtHT SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1189‑p, BRCA1 iso6 (human): , BRCA1 iso7 (human): S1189‑p, BRCA1 (mouse): S1152‑p, BRCA1 (rat): S1153‑p
Characterization
Methods used to characterize site in vivo immunoassay, mutation of modification site, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  MDA-MB-436 (breast cell), NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) inhibition of upstream enzyme, siRNA inhibition of enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
AG014699 increase
AG024322 AG014699 inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  cell growth, induced
Associated Diseases
Diseases Alterations Comments
breast cancer increased

S1191-p - BRCA1 (human)
Modsite: GELsRsPsPFtHTHL SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1191‑p, BRCA1 iso6 (human): , BRCA1 iso7 (human): S1191‑p, BRCA1 (mouse): S1154‑p, BRCA1 (rat): S1155‑p
Characterization
Methods used to characterize site in vivo immunoassay, mutation of modification site, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  MDA-MB-436 (breast cell), NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) inhibition of upstream enzyme, siRNA inhibition of enzyme
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  cell growth, induced
Associated Diseases
Diseases Alterations Comments
breast cancer increased

S1497-p - BRCA1 (human)
Modsite: EPGVERssPsKCPsL SwissProt Entrez-Gene
Orthologous residues
BRCA1 (human): S1497‑p, BRCA1 iso6 (human): S393‑p, BRCA1 iso7 (human): S1518‑p, BRCA1 (mouse): S1454‑p, BRCA1 (rat): S1455‑p
Characterization
Methods used to characterize site in vivo immunoassay, mutation of modification site, western blotting
Disease tissue studied:  breast cancer, breast cancer, triple negative, lung cancer, non-small cell lung cancer
Relevant cell lines - cell types - tissues:  MDA-MB-436 (breast cell), NCI-H1299 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDK1 (human) inhibition of upstream enzyme, siRNA inhibition of enzyme
Downstream Regulation
Effect of modification (function):  intracellular localization
Effect of modification (process):  cell growth, induced
Associated Diseases
Diseases Alterations Comments
breast cancer increased